Owlet Inc
$ 5.42
1.69%
14 Apr - close price
- Market Cap 150,095,000 USD
- Current Price $ 5.42
- High / Low $ 5.60 / 5.37
- Stock P/E N/A
- Book Value 0.71
- EPS -2.31
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.08 %
- ROE -8.02 %
- 52 Week High 16.94
- 52 Week Low 3.08
About
Owlet Inc. is a pioneering leader in infant health technology, dedicated to improving the safety and well-being of newborns through innovative monitoring solutions. Its flagship product, the Owlet Smart Sock, utilizes advanced pulse oximetry to provide continuous tracking of infants' heart rates and oxygen levels, offering critical health insights directly to parents' mobile devices. As the demand for pediatric health monitoring continues to rise, Owlet is well-equipped to expand its product offerings and enhance its market position in the rapidly evolving infant health sector. By prioritizing actionable data for parents and advancing pediatric care, Owlet is establishing a significant presence at the convergence of healthcare and technology.
Analyst Target Price
$14.25
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-06 | 2025-11-13 | 2025-08-08 | 2025-05-08 | 2025-03-05 | 2024-11-13 | 2024-08-12 | 2024-05-06 | 2024-03-07 | 2023-11-13 | 2023-08-14 | 2023-05-11 |
| Reported EPS | -0.03 | -0.06 | -2.28 | 0.11 | -0.07 | 0.03 | -0.3045 | -0.39 | -0.12 | -0.7 | -0.56 | -0.08 |
| Estimated EPS | -0.1133 | 0.2 | 0.1 | 0.04 | -0.48 | -0.24 | -0.19 | -0.14 | -0.04 | -0.36 | -0.37 | -0.09 |
| Surprise | 0.0833 | -0.26 | -2.38 | 0.07 | 0.41 | 0.27 | -0.1145 | -0.25 | -0.08 | -0.34 | -0.19 | 0.01 |
| Surprise Percentage | 73.5216% | -130% | -2380% | 175% | 85.4167% | 112.5% | -60.2632% | -178.5714% | -200% | -94.4444% | -51.3514% | 11.1111% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.26 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OWLT
2026-04-08 04:40:59
Owlet, Inc. CFO Amanda Crawford received 32,032 shares of common stock as her 2025 annual incentive bonus, valued at $157,531. Concurrently, 9,242 shares were withheld to cover tax obligations related to vested restricted stock units. After these transactions, Crawford directly holds 159,820 shares of Owlet common stock, with the stock bonus viewed as a routine compensation event rather than a discretionary market transaction.
2026-04-07 05:39:22
Jonathan Harris has resigned as President and Chief Executive Officer of Owlet (OWLT), effective immediately. Kurt Workman, a co-founder and former CEO, will return to assume the roles of President and CEO. Workman will also remain a director on the Board, having previously served as Executive Chair.
2026-04-07 05:10:31
Owlet (OWLT) anticipates its Q1 revenue to be at the high end of its $20M-$21M guidance range, aligning with the consensus of $20.67M. The company reemphasizes its long-term strategy centered on increasing adoption, expanding lifetime value, and leveraging data to evolve into a comprehensive pediatric health platform. CEO Kurt Workman, returning to his role, expressed commitment to this vision, highlighting efforts to boost market penetration and establish Owlet as the standard for at-home pediatric health.
2026-04-06 21:10:49
Owlet, Inc. has appointed co-founder Kurt Workman as its new President and CEO, effective April 6, 2026, replacing Jonathan Harris. Workman's compensation includes an annual salary of $500,000 and a 70% target cash performance bonus, along with Tier 1 protection in the Executive Change in Control Severance Plan. Jonathan Harris will receive 12 months of continued base salary, a prorated 2026 bonus, and accelerated vesting of all outstanding equity awards as part of his separation agreement.
2026-03-25 13:39:57
Owen Rickert of Northland Securities maintained a Buy rating on Owlet (OWLT) with a $15.00 price target. Joseph Catanzaro of Mizuho Securities reiterated a Buy rating on Avalo Therapeutics (AVTX), setting a $39.00 price target. Both companies received bullish sentiments from analysts in the Healthcare sector.
2026-03-11 07:51:56
Owlet, Inc. (NYSE: OWLT) shares fell on Monday after the company issued a disappointing first-quarter revenue outlook for 2026, though it reported a 29.6% year-over-year revenue increase for the previous period. Despite achieving record revenue and gross margin in 2025, primarily driven by its Owlet360 subscription service and Dream Sight camera, the negative forecast led to a significant drop in its stock price. The company projects Q1 2026 revenue of $20-21 million, below consensus, but anticipates full-year 2026 revenue of $126-130 million.
